Integra LifeSciences (NASDAQ:IART) Issues FY 2025 Earnings Guidance

Integra LifeSciences (NASDAQ:IART) updated its FY 2025 earnings guidance on Tuesday. The company provided EPS guidance of 2.410-2.510 for the period, compared to the consensus EPS estimate of 2.510. The company issued revenue guidance of $1.7 billion-$1.7 billion, compared to the consensus revenue estimate of $1.7 billion. Integra LifeSciences also updated its Q1 2025 guidance to 0.400-0.450 EPS.

Wall Street Analyst Weigh In

Several analysts recently commented on the stock. Citigroup increased their target price on shares of Integra LifeSciences from $16.00 to $22.00 and gave the company a “sell” rating in a research note on Tuesday, November 5th. Morgan Stanley assumed coverage on shares of Integra LifeSciences in a research note on Monday, December 2nd. They issued an “underweight” rating and a $20.00 price objective on the stock. Three investment analysts have rated the stock with a sell rating, five have given a hold rating and one has issued a buy rating to the company’s stock. According to data from MarketBeat.com, Integra LifeSciences currently has an average rating of “Hold” and a consensus target price of $23.00.

Integra LifeSciences Stock Up 4.4 %

Integra LifeSciences stock opened at $22.05 on Tuesday. The firm has a market capitalization of $1.70 billion, a price-to-earnings ratio of -244.97, a PEG ratio of 0.73 and a beta of 1.17. Integra LifeSciences has a fifty-two week low of $16.81 and a fifty-two week high of $44.91. The company’s 50 day simple moving average is $23.68 and its 200 day simple moving average is $21.81. The company has a debt-to-equity ratio of 0.79, a current ratio of 1.20 and a quick ratio of 0.73.

Insider Buying and Selling at Integra LifeSciences

In other news, EVP Michael J. Mcbreen sold 1,700 shares of the business’s stock in a transaction dated Monday, December 2nd. The shares were sold at an average price of $24.16, for a total value of $41,072.00. Following the completion of the sale, the executive vice president now owns 56,182 shares of the company’s stock, valued at approximately $1,357,357.12. The trade was a 2.94 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Corporate insiders own 3.10% of the company’s stock.

About Integra LifeSciences

Integra LifeSciences Holdings Corporation manufactures and sells surgical instruments, neurosurgical products, and wound care products for use in neurosurgery, neurocritical care, and otolaryngology. It operates in two segments, Codman Specialty Surgical and Tissue Technologies. The company offers neurosurgery and neuro critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment; and surgical headlamps and instrumentation, as well as after-market services.